Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
To read the full story
Related Article
- MHLW Pharma Bureau Seeks 13 Billion Yen for FY2021, Eyes Vaccine Quality Assurance Guidance in COVID-19 Quota
September 29, 2020
- MHLW Seeks Nearly 33 Trillion Yen in Unusual Budget Request for FY2021; COVID-19 Quota Yet to Come
September 29, 2020
- MHLW’s Health Policy Bureau Requests New Budgets to Forge Clinical Trial Network in Asia
September 29, 2020
- MHLW Explains Budget Request to LDP Lawmakers, Members Vigilant about Handling of Price Survey Results
September 25, 2020
- MHLW to Request Budgets for Survey on Prescribing Status, Safety of COVID-19 Meds Using MID-NET Database
September 25, 2020
REGULATORY
- New LDP Project Team Boots Up for Healthcare Transformation
May 8, 2024
- H5N1 Pre-Pandemic Flu Vaccine Selected for Stockpiling in FY2024
May 7, 2024
- Diagnostics of Original Biologics Can Be Used for Biosimilars Too: MHLW
May 7, 2024
- MHLW Project Team Compiles Interim Proposal for Supporting Healthcare Startups
April 30, 2024
- Govt’s Healthcare Advisors Call for Bolstering AMED Staff: 2025-2029 Strategy
April 30, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…